We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LINKING DEVICE MARKETING TO COMPLIANCE WILL HELP FIRMS ADAPT TO SHIFTING RULES

LINKING DEVICE MARKETING TO COMPLIANCE WILL HELP FIRMS ADAPT TO SHIFTING RULES

June 27, 2006

Device and diagnostics companies should integrate compliance standards more effectively into their sales and marketing efforts if they want to meet evolving regulatory requirements and avoid government enforcement actions, experts said at a recent industry conference.

Federal and state regulations are increasingly restricting the largesse firms can legally shower upon existing or prospective customers. As a result, aggressive promotional campaigns to purchasers are becoming a thing of the past and manufacturers need to revamp their way of doing business accordingly, Neal Roach, former vice president of ethics and compliance at Roche Diagnostics, said.

Agencies such as the HHS' Office of the Inspector General (OIG) pay close attention to promotions firms engage in with healthcare professionals (HCPs) that may breach fraud and abuse laws, said Roach, who is currently a partner with the law firm Sommer Barnard in Indianapolis. Addressing the Medical Device and Diagnostics Marketing Compliance Congress, June 20, he said firms should carefully monitor programs such as rebates, coupons, off-label promotions, consulting arrangements and physician training.

Roach suggested that firms build AdvaMed's code of ethics into their compliance programs. The code tells firms "how you can interact with your customers in ways that don't conflict with the anti-kickback statute."

The anti-kickback statute has existed since 1972 and "prohibits anyone from knowingly and willfully receiving or paying anything of value to influence the referral of federal healthcare program business," according to OIG. "Violations of the law are punishable by up to five years in prison, criminal fines up to $25,000, administrative civil money penalties up to $50,000, and exclusion from participation in federal healthcare programs," the agency notes.

The AdvaMed code reminds firms that, while they may provide reimbursement information to HCPs regarding their products, it is inappropriate for manufacturers to provide technical or other support "for the purpose of unlawfully inducing [HCPs] to purchase, lease, recommend, use, or arrange for the purchase, lease or prescription of [their] products." ()a href="http://www.fdanews.com/ddl/33_26/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 13Jun

    Winners Only: 3 Steps to Compete in Digital Quality

  • 14Jun

    Pharmaceutical Quality Risk Management and ICH Q9(R1): Navigating the Global Intersection of Principle and Regulation

  • 20Jun

    What’s CSA? And how can it streamline your GxP System Verification?

  • 22Jun

    Transforming Life Sciences Training: Top Trends Shaping Enterprise Learning Strategies

  • 12Jul

    FDA’s New Sterilization Pilot on Risk-Based Cleaning and Disinfectant Programs: Best Practices for Quality, Regulatory and Compliance Professionals

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Promosome Sues Moderna, Pfizer Over COVID-19 Patent Infringement

  • FDA Gives Warning Letter to iRhythm for Mislabeled Device, Unreported Deaths

  • Intarcia’s Request to Alter AdComm Procedures for Diabetes Treatment Denied

  • Cue Health’s First-of-its-Kind COVID-19 Home Test Gets FDA Authorization

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing